1. Introduction
===============

Mycotoxins are common contaminants of foods such as wheat, barley, grapes, coffee, spices, *etc*. and can affect the health of humans as well as livestock \[[@B1-toxins-06-00608]\]. Aflatoxin, ochratoxins, trichothecenes, zearelenone, fumonisins, tremorgenic toxins, and ergot alkaloids are the mycotoxins with the largest agro-economic importance \[[@B2-toxins-06-00608]\].

The fungal species *Fusarium* is one of the most common toxin-producing fungi of northern temperate regions and produces fumonisins, and trichothecenes. The trichothecenes are a large family of chemically related toxins and include T-2 toxinT-2, HT-2 toxin (HT-2), deoxynivalenol (DON), Diacetoxyscirpenol (DAS), Fusarenone-X (FUS-X), Nivalenol (NIV), diacetylnivalenol (DAS), neosolaniol and Zearalenone (ZEA \[[@B3-toxins-06-00608]\]). Mycotoxins of the *Fusarium* species are generally of two types: (1) the nonestrogenic TCs such as DON, (NIV), T-2, and (DAS); (2) the mycoestrogens, including ZEA \[[@B3-toxins-06-00608]\]. ZEA is a nonsteroidal, estrogenic mycotoxin and has been shown to be able to bind competitively to estrogen receptors \[[@B3-toxins-06-00608]\]. The mycoestrogens can induce an estrogenic response in targeted cells \[[@B4-toxins-06-00608]\], a finding which may enhance its synergistic effect with other with other trichothecenes (TCs) \[[@B3-toxins-06-00608]\]. The black mold Stachybotrys chartarum is also known to produce trichothecenes such as Satratoxin-G (SG) \[[@B5-toxins-06-00608]\].

Ochratoxin A (OTA), first discovered in 1965 in *Aspergillus ochraceus* has been subsequently reported in several *Aspergillus* and *Penicillium* species \[[@B6-toxins-06-00608],[@B7-toxins-06-00608]\]. Aflatoxins, produced by the *Aspergillus* species are considered to be serious food contaminants worldwide \[[@B8-toxins-06-00608]\], and aflatoxin B1 (AFB1) is a well-known carcinogen and genotoxic agent \[[@B9-toxins-06-00608]\].

While there has been much research into the mechanisms of damage related to mycotoxins, the link between metabolism, toxicity and carcinogenicity of mycotoxins remains incompletely understood \[[@B10-toxins-06-00608]\]. Mycotoxins occur in many foods and in low doses, mycotoxins such as aflatoxin generally do not cause health problems as they are bound to glutathione via interaction with the enzyme glutathione S-transferases (GST), which facilitates the excretion of mycotoxin \[[@B11-toxins-06-00608]\]. Thus, both the availability of reduced glutathione and the GST enzymes are important in the prevention of mycotoxin-related pathology. Much of the work on mycotoxins has focused on their association with cancer. AFB1, a difurancoumarin mycotoxin produced by the mold *Aspergillus flavus*, is a potent, naturally occurring carcinogen \[[@B12-toxins-06-00608]\]. The early observations that an epoxide of AFB1 created adducts with DNA led to the concept that mycotoxin-DNA adducts, such as AFB1-DNAs, initiate cancer---an observation which has been documented *in vitro* and *in vivo* \[[@B13-toxins-06-00608],[@B14-toxins-06-00608]\].

In addition to carcinogenesis, toxicity is associated with mycotoxins. For example, in regard to aflatoxin, an AFB1 dialdehyde has been proposed as a toxin whose damage is also diminished by conjugation with GST \[[@B15-toxins-06-00608],[@B16-toxins-06-00608]\]. Early research on aflatoxin led to the identification of DNA adducts as a significant factor in the genetic and general toxicity of this mycotoxin and many subsequent studies focused on mycotoxin-related adducts \[[@B17-toxins-06-00608],[@B18-toxins-06-00608]\]. Some confusion regarding the mechanism of mycotoxin toxicity as the formation of adducts was not found with other mycotoxins, such as ochratoxin A (OTA) \[[@B19-toxins-06-00608],[@B20-toxins-06-00608]\]. Interest in the mechanism of action of mycotoxins and especially OTA has increased with the availability of a Clinical Laboratory Improvement Amendments (CLIA) regulation-compliant registered laboratory test, which has identified OTA in the urine of humans with chronic illness \[[@B21-toxins-06-00608],[@B22-toxins-06-00608]\]. One of the clinical studies identified OTA in 83% of over 100 individuals tested with chronic illness and a history of water-damaged building exposure \[[@B22-toxins-06-00608]\]. These findings suggest that an increased understanding of the pathophysiology of mycotoxin-related illness may be useful in designing treatment for these problems.

Continued studies on OTA led to the observation that oxidative stress was a possible key factor in the toxicity and genotoxicity of OTA \[[@B23-toxins-06-00608],[@B24-toxins-06-00608],[@B25-toxins-06-00608],[@B26-toxins-06-00608]\]. OTA was shown to increase the formation of oxidative products of lipids, with increased production of malondialdehyde (MDA), a product of the interaction of polyunsaturated lipids and free radicals \[[@B24-toxins-06-00608],[@B27-toxins-06-00608],[@B28-toxins-06-00608]\]. It was shown that the toxicity of OTA could be decreased by maintaining glutathione production with *N*-acetyl cysteine (NAC), which decreased reactive oxygen species (ROS) and 8-oxoguanine formation. These findings suggested that cellular glutathione (GSH) levels play a significant role in limiting the toxicity of the mycotoxin OTA \[[@B29-toxins-06-00608]\].

Recent reviews suggest both direct, DNA adduct-mediated mechanism \[[@B30-toxins-06-00608]\] and an oxidative stress-mediated mechanism as causes of the carcinogenicity of OTA. It appears that that oxidative stress plays a significant role in the toxicity of mycotoxins \[[@B31-toxins-06-00608],[@B32-toxins-06-00608],[@B33-toxins-06-00608],[@B34-toxins-06-00608]\]. The focus of this review is the effect of mycotoxins on intracellular glutathione and the multifactorial function of glutathione as an antioxidant and detoxifier as well as the loss of glutathione as a significant factor in the pathogenesis of illnesses related to mycotoxin accumulation.

2. Oxidative Stress
===================

The concept of oxidative stress has developed from the free radical theory of oxygen toxicity developed in the 1950s with studies such as those by Rebecca Gerschman showing that oxygen poisoning and X-irradiation can both produce oxygen-derived free radicals \[[@B35-toxins-06-00608],[@B36-toxins-06-00608]\]. It has been known since the writing by Lavoisier in the late 1700s that oxygen can cause damage to the lipids of animal cells \[[@B37-toxins-06-00608]\], as recounted in \[[@B38-toxins-06-00608]\]. The studies of ionizing radiation demonstrated that free radicals of oxygen can be generated not only by ionizing radiation, but were also formed during normal oxidative metabolism. These processes formed radicals such as hydroxyl radicals OH^•^, hydroperoxyl radicals H O~2~^•^ and peroxide H~2~O~2~ \[[@B35-toxins-06-00608]\].

Oxidative stress occurs when there is an increase in the production of free radicals and reactive metabolites, which are termed oxidants and which exceed the ability of the cell to eliminate the oxidants by protective mechanisms, termed antioxidants. This excess of oxidants leads to the damage to the biomolecules of cells, tissues and organs with a potentially harmful impact on the whole organism. The constant interaction between oxidants and antioxidant function is part of the normal function of cells and can lead to differences in glutathione concentrations within cellular and tissue compartments \[[@B39-toxins-06-00608]\].

3. Glutathione Sources in the Body
==================================

Composed of glutamine, cysteine, and glycine and utilized as an antioxidant, GSH is the main nonprotein thiol responsible for cellular homeostasis and maintenance of the cellular redox balance \[[@B40-toxins-06-00608],[@B41-toxins-06-00608]\]. Existing in two forms, oxidized (GSSG) and reduced/free form (GSH), only GSH exhibits antioxidant activity. During oxidative stress, GSH is utilized to neutralize reactive oxygen species leading to the formation of GSSG. GSSG is the by-product of the free radical-scavenging activity of GSH and lacks antioxidant function \[[@B40-toxins-06-00608],[@B41-toxins-06-00608]\].

Production of GSH occurs by two mechanisms, *de novo* synthesis and recycling of GSSG. *De novo* synthesis occurs in a two-step reaction catalyzed by two separate enzymes, glutamine-cysteine ligase (GCL) and glutathione synthase (GS), as shown in [Figure 1](#toxins-06-00608-f001){ref-type="fig"}. The first step in the reaction is catalyzed by GCL, a heterodimer made up of a catalytic subunit (GCLC) that possesses the enzyme's active site and performs the actual amino acid linkage, and a modulating subunit (GCLM) that regulates the activity of GCLC, as reviewed in [Figure 1](#toxins-06-00608-f001){ref-type="fig"}. This first step is rate limiting, with cysteine availability being the rate-limiting component \[[@B40-toxins-06-00608],[@B41-toxins-06-00608]\]. In the final step of *de novo* GSH synthesis, glycine is linked to the dimer formed in the previous step reaction by GS. *De novo* synthesis of GSH is regulated by negative feedback.

![Production of GSH occurs by two mechanisms, *de novo* synthesis and recycling of GSSG. *De novo* synthesis occurs in a two-step reaction catalyzed by two separate enzymes, glutamine-cysteine ligase (GCL) and glutathione synthase (GS). The enzyme glutathione reductase (GSR) catalyzes the reduction of GSSG back to GSH. Glutathione peroxidase (GSH-PX) is a selenium-based enzyme that reduces hydrogen peroxide (H~2~O~2~) to water.](toxins-06-00608-g001){#toxins-06-00608-f001}

Gamma-glutamyltransferase 1 (GGT1) is a membrane-bound enzyme that catalyzes the breakdown of extracellular GSH into glutamate and cysteinyl-glycine, providing raw materials for the *de novo* of GSH \[[@B42-toxins-06-00608],[@B43-toxins-06-00608],[@B44-toxins-06-00608]\].

Finally, GSH can be obtained by the reduction of GSSG via the glutathione reductase (GSR) enzyme. This reaction requires NADPH and forms two GSH molecules from one GSSG molecule \[[@B40-toxins-06-00608],[@B41-toxins-06-00608]\]. It is now known that a number of interactions may occur that prevent the *de novo* formation of GSH. For example, it has been shown that glutathione is decreased due to an inability to produce glutathione in the extracellular lung fluid of children with chronic asthma \[[@B45-toxins-06-00608]\] and in the macrophages of adults with human immunodeficiency virus (HIV) \[[@B46-toxins-06-00608]\].

3.1. Gene Control of GSH Production
-----------------------------------

Glutathione biosynthesis, glutathione peroxidases, glutathione S-transferases and glutathione S-conjugate efflux pumps function in a coordinated fashion to facilitate a coordinated response to oxidative stress. Regulation of this response is facilitated by the antioxidant responsive element (ARE) which is located in the promoters of many of the genes that are induced by oxidative and chemical stress \[[@B47-toxins-06-00608]\].

The investigation of the mechanism of glutathione deficiency in the lungs children with asthma has shown that dysregulation of glutathione-related antioxidant defense occurs due to dysfunction of a transcription factor that stimulates gene expression of the enzymes related to the antioxidant defense and glutathione production in cells. The transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a transcription factor with a basic leucine zipper motif that plays a key role in redox regulation. Nrf2 is expressed the majority of cell types, where it is anchored in the cytosol by an inhibitory protein, Kelch-like ECH-associated protein (Keap1). With an increase in oxidative stress, Nrf2 is released and translocates to the nucleus, where it binds and activates the ARE and upregulates several genes associated with glutathione synthesis and antioxidant defense ([Figure 2](#toxins-06-00608-f002){ref-type="fig"}) \[[@B45-toxins-06-00608],[@B48-toxins-06-00608]\].

![The transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) plays a key role in redox regulation. Nrf2 is expressed by the majority of cell types; it is anchored in the cytosol by an inhibitory protein, Kelch-like ECH-associated protein (Keap1). During oxidative stress, Nrf2 is released and transfers to the nucleus, where it binds and activates the antioxidant response elements (ARE) and upregulates the expression of several genes associated with antioxidant defense and glutathione (GSH) synthesis.](toxins-06-00608-g002){#toxins-06-00608-f002}

It has been shown that compromise of Nrf2 function can occur due to modification of Nrf2 after production, even when its production is upregulated \[[@B45-toxins-06-00608]\]. It appears that excess oxidative stress causes posttranslational modification of Nrf2. Without Nrf2 function, the genes that form GCL and GS are not expressed with the result that GSH is not formed. The damaging effects of Nrf2 modification in the lung, as an example, may increase the susceptibility of the affected tissues to the oxidative stress of the oxygen environment, as well as compromise the function of epithelial cells and phagocytes, such as granulocytic leukocytes and monocytes/macrophages \[[@B49-toxins-06-00608],[@B50-toxins-06-00608]\].

The importance of Nrf2 function is shown in an animal model in which the upregulation of Nrf2 will protect against dietary carcinogen diethylnitrosamine (DENA)-induced liver carcinogenesis \[[@B51-toxins-06-00608]\].

Similar compromise of gene up-expression has been shown to occur in macrophages obtained from individuals with HIV infection \[[@B52-toxins-06-00608]\]. This study demonstrates that without function of the genes needed to produce glutathione supplying the building block of glutathione production, NAC is much less efficient than supplying the whole molecule of glutathione using a liposomal encapsulation of glutathione \[[@B46-toxins-06-00608]\].

3.2. Cytokine Influence on GSH Production
-----------------------------------------

In the macrophages of individuals with HIV, the gene expression for the formation of the enzymes of GSH synthesis GCLC, GCLM, GSS, and GGT1 appear to be down-regulated \[[@B53-toxins-06-00608]\]. Down-regulation of the GCLC gene results in decreased synthesis of GSH that is related to an increased formation of an inflammatory cytokine called transforming growth factor-β (TGF-β) \[[@B54-toxins-06-00608],[@B55-toxins-06-00608]\]. It has been shown that decreased levels of GSH will stimulate production of TGF F-β and that when GSH is replenished, the production of TGF-β will be decreased \[[@B56-toxins-06-00608]\].

3.3. Glutathione S-Transferase
------------------------------

Nrf2 transcription also controls the formation of Glutathione S-transferases (GSTs). Glutathione S-transferase is a multi-isoform family of enzymes that detoxify endobiotic and xenobiotic compounds. Each subunit of the dimeric GST enzyme has an active site composed of two distinct functional regions: a hydrophilic G-site, which binds the physiological substrate glutathione, and an adjacent H-site which provides a hydrophobic environment for the binding of structurally diverse electrophilic substrates \[[@B57-toxins-06-00608]\]. This structure allows GSTs to catalyze the nucleophilic attack of glutathione (GSH) \[[@B58-toxins-06-00608]\] on electrophilic substrates, which decreases the electrophile's reactivity with cellular macromolecules \[[@B57-toxins-06-00608]\]. In humans and rodents, the soluble GSTs are collectively expressed in relatively large amounts, and may comprise as much as 4% of total soluble protein in the liver \[[@B58-toxins-06-00608]\].

3.4. GST Genetic Polymorphisms
------------------------------

The level and molecular form of glutathione is a key determinant of the cellular response to oxidative stress \[[@B59-toxins-06-00608]\] and the interaction with glutathione S-transferase (GST) will affect the level of glutathione \[[@B47-toxins-06-00608]\]. GSTs function by conjugating reduced GSH and catalyzing the attack on foreign compounds or oxidative stress products, generally forming less-reactive materials that can be readily excreted. There are three distinct families of GSTs in mammals: cytosolic, mitochondrial and membrane-associated proteins. Cytosolic GSTs represent the largest family and is subdivided into seven classes based on their amino acid sequence (mu, pi, theta, alpha, sigma, omega and zeta). The GST within a particular class typically share more than 40% of their identity, but at least five of the human GST genes display functional polymorphisms. These polymorphisms are likely to contribute to the difference between individuals in responses to xenobiotics and clearance of oxidative stress products and have been associated with various pathologies such as cancer, and cardiovascular or respiratory diseases \[[@B60-toxins-06-00608]\]. Individuals homozygous for the GSTM1 deletion polymorphism represent approximately 50% of the population and lack expression of this enzyme in any tissue in the body \[[@B58-toxins-06-00608]\]. The implication of GST polymorphisms may be significant as studies suggest that that loss of mu, pi and theta GST genes increase susceptibility to inflammatory diseases, and a genetic deficiency of GSTM1 is associated with increased susceptibility to ozone-related asthma \[[@B61-toxins-06-00608]\] and to susceptibility to AFB1-mediated damage to human liver cells \[[@B62-toxins-06-00608]\]. These authors suggested that individuals with GSTM1 polymorphism may benefit from antioxidant supplementation. The combination of GSTM1 null and GSTP1 Val was significantly associated with an increased risk of lung cancer \[[@B63-toxins-06-00608]\] and hepatocellular carcinoma \[[@B64-toxins-06-00608]\]. An inverse relationship between plasma selenium level, an indicator of the function of glutathione peroxidase and AFB1--albumin adducts were observed to be statistically significant among individuals with null genotypes of GSTM1 and GSTT1, but not among the non-null genotypes \[[@B65-toxins-06-00608]\]. In carriers of hepatitis B virus, there was an increased risk of HCC in null genotypes of GSTM1 and T1 but not among individuals who had non-null genotypes \[[@B66-toxins-06-00608]\]. Additionally, GSTM1 null genotype is a risk factor for Alzheimer's disease \[[@B67-toxins-06-00608]\] and T-2 can suppress drug-metabolizing enzymes such as the GSTs \[[@B68-toxins-06-00608]\] and related oxidative stress-associated pathways \[[@B68-toxins-06-00608]\].

4. Identification of Mycotoxin-Related Oxidant Stress
=====================================================

OTA causes a variety of toxic presentations in animals with renal toxicity---a prominent and consistent finding \[[@B69-toxins-06-00608],[@B70-toxins-06-00608]\]---with these cells showing inhibition of protein synthesis \[[@B71-toxins-06-00608]\], impairment of energetic metabolism and changes in cell phenotype in renal cells \[[@B72-toxins-06-00608]\], as well as increased oxidative stress \[[@B24-toxins-06-00608],[@B26-toxins-06-00608],[@B72-toxins-06-00608]\].

These findings led to the use of toxicogenomic profiles for analysis of the cellular responses to OTA. The evidence that OTA caused increased oxidative stress led to the expectation that gene expression profiles after exposure to OTA in animals would show the induction of many genes responsive to exposure to oxidative stress. Surprisingly, in tissue samples expected to be damaged by OTA, such as kidney, it was found that OTA caused a down-regulation of genes expected to be stimulated by oxidant exposure. A study of rats exposed chronically to OTA, even at doses that resulted in 25% of the animals developing kidney tumor formation, the gene expression profile showed down-regulation of the antioxidant genes \[[@B73-toxins-06-00608]\]. In these studies, OTA induced tissue-specific responses identified in kidney *versus* liver. Applying toxigenomic assessment to the studies of OTA revealed several data to help explain the mechanism of action of OTA. For example, OTA induced strong down-regulation of regucalcin, which interferes with intracellular calcium regulation, a finding associated with nephrotoxic and nephrocarcinogenic compounds such as cisplatin \[[@B74-toxins-06-00608],[@B75-toxins-06-00608]\]. It was also shown that renal transport proteins that facilitate the urinary excretion of OTA, as well as multidrug resistance (MDR) proteins, were down-regulated \[[@B73-toxins-06-00608]\]. The tissue injury associated with OTA was accompanied by a disruption of pathways related to the transcription factors hepatocyte nuclear factor 4 alpha (HNF4α) and nuclear factor-erythroid 2-related factor 2 (Nrf2) \[[@B73-toxins-06-00608]\]. Many Nrf2-regulated genes are involved in chemical detoxification and antioxidant defense \[[@B76-toxins-06-00608]\]. The findings suggested that depletion of these genes results in a decrease of the oxidant defense mechanism that was a likely cause of damage to both cell and genetic functions in cells \[[@B73-toxins-06-00608]\].

It appears that an active transport mechanism concentrates OTA in the kidney, which results in the toxicity of OTA \[[@B77-toxins-06-00608],[@B78-toxins-06-00608]\]. While the impact of OTA appears to be related to its concentration in the kidney, sufficiently high levels of OTA will cause oxidant damage in any organ tissue \[[@B79-toxins-06-00608]\].

Exposure to OTA can down-regulate the formation of GCLC, the rate-limiting enzyme in GSH synthesis, which will result in a reduction in the intracellular level of GSH \[[@B73-toxins-06-00608]\]. The block of the GCLC enzyme may explain the decrease of GSH previously found in OTA-treated cell cultures \[[@B29-toxins-06-00608]\]. In addition to decreasing GSH, OTA inhibition of Nrf2 expression will decrease the production of the GST isoform GSTP1, which facilitates the detoxification of the lipid peroxidation product 4-hydoxynonenal (4-HNE) by facilitating the conjugation of 4-HNE with GSH. The reactive chemical 4-HNE is known to bind and form adducts to macromolecules including DNA \[[@B80-toxins-06-00608]\], and cell culture studies demonstrate that Nrf2 and glutathione are needed to protect cells from 4-HNE and lipid peroxidation toxicity \[[@B81-toxins-06-00608]\]. Thus, the formation of GST and GCL are central to the detoxification of OTA and the loss of formation of the antioxidant, detoxification enzymes related to glutathione suggests that OTA inhibits its own detoxification \[[@B82-toxins-06-00608]\].

The findings of increased oxidant stress related to decreased expression of Nrf2 in kidney cells suggests that direct binding of the mycotoxin to DNA is not needed to create DNA damage \[[@B79-toxins-06-00608]\]. The down-regulation of Nrf2 genes results in a decrease in antioxidant defense is due to the decreased expression of Nrf2-related antioxidant genes and thus, the oxidative stress induced by OTA may account for both the genetic damage and the cytotoxicy related to OTA \[[@B79-toxins-06-00608]\]. Thus, the oxidative damage mediated by OTA may be divided into the direct (covalent DNA adduction) and indirect (oxidative DNA damage) mechanisms \[[@B83-toxins-06-00608]\]. Trichothecene type mycotoxins such as T-2 toxin have also been shown to cause cell damage by increasing oxidative stress and depleting glutathione \[[@B84-toxins-06-00608]\].

5. Mycotoxin Effect on Immunity is Oxidative Stress Related
===========================================================

AFB1 mainly affects cell-mediated immunity and has also been shown to increase inflammation \[[@B85-toxins-06-00608]\]. T-2 toxin, can decrease the function of the innate immune system \[[@B86-toxins-06-00608]\]. Both AFB1 and FB1 are carcinogenic and modulate immunity \[[@B18-toxins-06-00608]\]. Both AFB1 and FB1 increase ROS and stimulate biomolecular oxidative damage in spleen mononuclear cells; the combination appears to have even stronger pro-oxidant activity \[[@B87-toxins-06-00608]\]. A similar immunosuppression has been demonstrated by the combination of DON, and FB1 \[[@B88-toxins-06-00608],[@B89-toxins-06-00608]\] combination increase ROS in spleen mononuclear cells \[[@B87-toxins-06-00608]\]. These results demonstrate that immune cells are affected by mycotoxins and that oxidative stress is a major component of the damage in these cells.

Additional suggestion that the interaction between glutathione and mycotoxin plays an important role in immune cell function comes from studies of the mycotoxins gliotoxin and patulin which show that in murine dendritic cells (antigen-presenting macrophage cells), the mycotoxins depleted glutathione in a concentration-dependent fashion \[[@B90-toxins-06-00608]\]. Respiratory exposure to gliotoxin or ingestion of patulin increased the asthma-like phenotype in an animal model and additionally increased chronic airway inflammation \[[@B90-toxins-06-00608]\]. Both gliotoxin and patulin have been shown to shift the Th1/Th2 balance toward a Th2 response \[[@B91-toxins-06-00608],[@B92-toxins-06-00608]\]. Mycotoxins were shown to decrease glutathione in PBMC and alveolar cells \[[@B92-toxins-06-00608],[@B93-toxins-06-00608]\].

The central role of glutathione in a variety of cell functions related to immune defense has been demonstrated in previous studies. It has been shown that a decrease in glutathione in antigen-presenting cells correlates with increased Th2 response \[[@B94-toxins-06-00608],[@B95-toxins-06-00608]\]. Decreased glutathione found in macrophage cells from children with chronic asthma has been shown to be related to decreased bacterial phagocytosis \[[@B96-toxins-06-00608]\]. In the children with chronic asthma, the decrease in glutathione was shown to be related to post-translational modification of Nrf2, which resulted in decreased gene expression of the enzymes of glutathione production. Decreased glutathione and decreased macrophage defense against intracellular infection with *Mycobacterium tuberculosis* occurs in the macrophages of individuals with HIV \[[@B52-toxins-06-00608]\]. The decrease in glutathione in the macrophage of HIV^+^ individuals was shown to be due to a decrease in the gene expression of the enzymes of glutathione production \[[@B52-toxins-06-00608]\].

Restoration of glutathione levels in the mycotoxin exposed mouse dendritic cells using NAC or glutathione ethyl ester restored IL-12 secretion and prevented the mycotoxin-induced increase of airway inflammation and airway hyperreactivity \[[@B90-toxins-06-00608]\]. Similarly, restoration of glutathione using NAC in the macrophages of children with asthma restored phagocytosis in the *ex vivo* model \[[@B96-toxins-06-00608]\]. The loss of glutathione in the HIV^+^ macrophages has been shown to be related to decreased cell defense against *Mycobacterium tuberculosis* replication \[[@B52-toxins-06-00608]\].

6. Conclusions
==============

Evidence that oxidative stress is a significant factor in the pathophysiology of mycotoxin-related illness is accumulating. The evidence that OTA-related oxidative stress is a factor in nephrocarcinogenicity has been demonstrated in a comprehensive review \[[@B31-toxins-06-00608]\]. The demonstration that the oxidative stress associated with mycotoxins can be related to direct suppression of GCLC gene function, post-translational modification of Nrf2 or the presence of excess TGF-β suggests that the lack of glutathione may be due to the inability of mycotoxin-affected cells to adequately form glutathione. Decreased function of the enzymes of glutathione production results in a microenvironment depleted of glutathione on a chronic basis. In humans, deficiency of glutathione can lead to chronic conditions \[[@B97-toxins-06-00608]\], including chronic asthma \[[@B45-toxins-06-00608]\]. A decrease in glutathione due to mycotoxin-related depletion may contribute to the range of conditions associated with mycotoxin accumulation \[[@B22-toxins-06-00608]\]. The lack of function of the enzymes of glutathione production in these conditions suggests that more efficient resolution of the effects of glutathione depletion may require the administration of the complete molecule as demonstrated *in vitro* in the HIV^+^ macrophage study \[[@B52-toxins-06-00608]\]. These observations echo an early report regarding the benefit of glutathione in the management of aflatoxin-related hepatocellular carcinoma in an animal model, which proposed that administration of the intact glutathione molecule was needed for benefit of the use of glutathione \[[@B98-toxins-06-00608]\]. Anecdotal reports suggest that studies using liposomal glutathione in the management of mycotoxin-related conditions may be warranted \[[@B21-toxins-06-00608],[@B99-toxins-06-00608]\].

Guilford is the Managing partner of You Energy Systems, LLC, which manufactures ReadiSorb^©^ glutathione, a brand of liposomal glutathione.
